Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.47 |
| ▸ | YAP1 | P46937 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | USP19 | O94966 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7657420 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL25426557 | 0.95 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL6892070 | 0.91 | GRIN2B (0.50) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL20339027 | 0.91 | PARP1 (0.46) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL4400064 | 0.90 | FAAH (0.49) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL29132096 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL29132098 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL29132404 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL25295183 | 0.87 | YAP1 (0.46) | SMN1; SMN2NPC1RAB9AHTTKDM4E | |
| SCHEMBL30288951 | 0.86 | DRD2 (0.52) | SMN1; SMN2NPC1RAB9AHTTUSP19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234939-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-4204090-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
| CN-115989225-A | Imidazole-pyrazole derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022043486-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-03-03 | — | — | WO | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| US-6680312-B2 | FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6403595-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1054005-A1 | SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | SMN1; SMN2 4142/4885NPC1 2223/4885RAB9A 1986/4885 |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | F12, F11, F2 | SMN1; SMN2 2803/4885NPC1 4444/4885RAB9A 3693/4885 |
| US-20230234939-A1 | IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS | CYP3A7, NISCH, ARG1 | SMN1; SMN2 4195/4885NPC1 1365/4885RAB9A 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.